Evofem Biosciences Q1 sales edge up on higher pricing

Evofem Biosciences

18/05/2026 14:05

Overview

US women's health pharma Q1 sales rose slightly yr/yr, net loss reversed prior yr profit

Company attributed sales growth to higher pricing and favorable gross-to-net ratios for both products

Company expanded global reach with new distribution agreement for SOLOSEC in Sub-Saharan Africa

Outlook

Evofem expects non-dilutive capital from MENA and Sub-Saharan Africa markets in 2026

Company says UAE regulatory review for PHEXX and SOLOSEC is ongoing

Result Drivers

HIGHER PRICING - Co said Q1 sales growth was primarily driven by higher WAC and more favorable gross-to-net ratios for both PHEXX and SOLOSEC

LOWER PHEXX SALES - Q1 PHEXX ex-factory sales fell due to high wholesaler purchases in December 2025 ahead of price hike

Company press release: ID:nBw84D28Za

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
$899,000
Q1 Net Income
-$5.47 mln
Q1 Income from Operations
-$4.57 mln
Q1 Pretax Profit
-$5.47 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)